Blood myelin oligodendrocyte glycoprotein level as an indicator of disease activity in multiple sclerosis

Unsong Oh[1], Elizabeth Brew[1], Abena Kwegyir-Aggrey[1], Fatma Mufti[1], Stepanie Buxhoeveden[2], Julie McVoy[1], Ryan Canissario[1], Myla D. Goldman[1]

1. Virginia Commonwealth University School of Medicine, Department of Neurology, Richmond, VA, U.S.A.
2. Accelerated Cure Project, Waltham, MA, U.S.A.

ABSTRACT

Background

Biomarkers that are informative with regards to the degree of demyelination associated with disease activity in multiple sclerosis may aid in prognostication and treatment considerations. Protein components of myelin, such as myelin oligodendrocyte glycoprotein (MOG), are potential biomarkers of demyelination, but questions remain about the significance and utility of blood MOG protein levels in multiple sclerosis.

Methods

In a case-control study, MOG protein levels were compared in serum samples from individuals with multiple sclerosis and controls. Cerebrospinal fluid (CSF) MOG protein levels were measured in a subset of the cases. Serum neurofilament levels were also measured for comparison.

Results

Serum MOG protein levels were higher in individuals with multiple sclerosis than those with a primary headache diagnosis (non-inflammatory neurological controls) and healthy donors. ROC curve analysis indicated good discrimination between multiple sclerosis and controls based on serum MOG protein levels. Correlation between serum and CSF MOG protein levels was moderate. Higher MOG protein levels were associated with clinical disease activity in multiple sclerosis and incrementally added to information provided by serum NfL levels. There was a moderate correlation between serum MOG and serum NfL levels.

Conclusion

MOG protein levels are elevated in the blood of individuals with multiple sclerosis and may be associated with disease activity.

INTRODUCTION

Multiple sclerosis is an inflammatory demyelinating disease of the central nervous system (CNS). Pathology is notable for varying degrees of demyelination and axonal injury. Whereas denuded axons from demyelination are considered the substrate for potential remyelination, axonal degeneration is considered irreparable. Biomarkers that are informative with regards to the relative degrees of demyelination versus axonal injury associated with multiple sclerosis disease activity may aid in prognostication, guide treatment considerations and enhance our understanding of disease mechanisms.

Myelin oligodendrocyte glycoprotein (MOG) is a component of myelin enriched in the outer layer of myelin sheath (Brunner et al. 1989). MOG is considered to be primarily of CNS origin, and is therefore a potentially more specific marker of CNS demyelination than others such as myelin basic protein (MBP) that are also expressed in the periphery (Pribyl et al. 1993). While antibodies against MOG (i.e. anti-MOG IgG) have been well studied and shown to distinguish MOG antibody disease (MOGAD) from multiple sclerosis, less is known about the usefulness of MOG protein as a biomarker in multiple sclerosis.

We measured blood levels of MOG protein and assessed its potential as an indicator of diagnosis and disease activity in individuals with multiple sclerosis. To assess the significance of serum MOG levels in multiple sclerosis, we (1) compared serum MOG levels of multiple sclerosis patients with those of controls, (2) compared serum MOG in subjects from multiple sclerosis patients in clinical relapse and remission and (3) compared serum MOG and serum neurofilament light chain (NfL) levels, a marker of neuroaxonal injury.

METHODS

Samples

Cohort 1. Virginia Commonwealth University Multiple Sclerosis Biorepository (VCU MS biorepository). Archived blood samples from subjects with multiple sclerosis and primary headache syndromes (non-inflammatory neurological controls) available from a local institutional review board-approved biorepository were used for this study. Subjects were recruited for participation between June 2014 and 2024. Subjects with multiple sclerosis met published diagnostic criteria (Thompson et al. 2018). Subjects with primary headache syndromes had no neurological diagnoses other than headache. Clinical relapse was defined as the appearance of new or recurrent symptoms attributable to multiple sclerosis lasting > 24 hours, in individuals with at least 30 days of

preceding neurologic stability, in the absence of fever and with associated objective findings on a neurologist's examination leading to a change in functional system scores. All subjects provided written informed consent. Standard operating protocol was followed for collection and storage of blood samples. In short, serum was processed from peripheral blood obtained by venipuncture in serum separator tubes then aliquoted into cryovials and stored frozen at -80°C. Samples were thawed on ice at the time of the assays.

Cohort 2. Accelerated Cure Project biorepository (ACP biorepository). Serum samples from an independent cohort of multiple sclerosis and healthy donors were obtained from the Accelerated Cure Project biorepository.

Biomarkers

MOG protein levels were measured using a commercially available human MOG ELISA kit (Abcam, #Ab278115) according to the manufacturer's protocol. Briefly, test samples or standards were incubated in solution with an anti-MOG antibody cocktail consisting of an affinity-tagged capture antibody and an HRP-conjugated detection antibody in microtiter wells precoated with an anti-affinity tag antibody to which the complexes became immobilized. After washing to remove unbound material, 3,3',5,5'-tetramethylbenzidine development solution was added to the wells for colorimetric analysis performed on a plate reader (Synergy HT, Biotek). Each ELISA plate contained samples from multiple sclerosis and controls. Mean intra-assay coefficient of variation (CV) was 3.4% and mean inter-assay CV was 11.5% for the MOG ELISA. Serum Neurofilament light chain (NfL) was measured on the Simoa instrument platform (SR-X, Quanterix) using a commercially available kit (NF-light Advantage V2, Quanterix) according to the manufacturer's protocol. Intra- and inter-assay CV was less than 10% for the NfL assay.

Statistical analysis

Mean, standard deviation and 95% confidence intervals (95% CI) were determined for study parameters. Proportions (%) were determined for categorical variables. Estimation statistics (Ho et al. 2019) were used to determine the 95% CI of the difference in means between samples. For p-value determinations, Mann-Whitney test of significance was used for two-sample comparisons. Fisher's exact test was used to compare categorical variables. Receiver operating characteristic (ROC) curve analysis was performed. Spearman correlation analysis was done for raw data and Pearson correlation analysis was done for log transformed data.

Estimation statistics were performed on the Estimation Stats Web App (estimationstats.com). GraphPad Prism software was used for all statistical analysis other than estimation statistics.

RESULTS

Blood MOG protein levels are higher in multiple sclerosis compared to controls

We measured serum MOG levels from cohort 1 samples, comparing individuals with multiple sclerosis who had never been on disease modifying therapy (DMT-naive) and those with a diagnosis of primary headache syndromes (non-inflammatory neurological disease controls). Demographics of DMT-naive multiple sclerosis and controls and their mean serum NfL levels are shown in Table 1. As shown in Figure 1A, the serum MOG protein levels were higher in DMT-naive multiple sclerosis compared to those with a primary headache diagnosis with a mean difference of 27.4 pg/ml (95% CI 15.8, 41.0). A second, independent cohort of individuals with multiple sclerosis and healthy donors was tested for serum MOG protein levels. Demographics of cohort 2 samples and their mean NfL levels are shown in Table 2. Serum MOG protein levels from individuals with multiple sclerosis were higher than those of healthy donors (Figure 1B), with a mean difference of 19.7 pg/ml (95% CI 11.5, 27.4). Receiver operating characteristic (ROC) analysis was performed on pooled data from the 2 cohorts to assess to what extent MOG protein levels discriminate between multiple sclerosis and controls (healthy donors and headache syndromes). ROC analysis of serum MOG protein levels for multiple sclerosis and controls showed an area under the curve (AUC) of 0.81 (95% CI 0.73 to 0.89, $p < 0.0001$), indicating good discrimination between multiple sclerosis and controls (Figure 1C). For cases from cohort 1 that had paired cerebrospinal fluid (CSF) and serum samples available, MOG protein levels were also measured in the CSF. Analysis showed a moderate correlation between cerebrospinal fluid and serum MOG protein levels (Pearson $r = 0.47$, $p = 0.01$, Figure 1D).

Blood MOG protein levels are associated with clinical disease activity in multiple sclerosis

To assess the utility of blood MOG protein levels as a biomarker of disease activity in multiple sclerosis, we compared MOG protein levels in samples from individuals with multiple sclerosis experiencing a clinical relapse (MS in relapse) to those in clinical remission (MS in remission). Demographics of the cohort and mean NfL levels for cases and controls are shown in Table 3. As shown in Figure 2, serum MOG protein levels for MS in relapse was significantly higher than those of MS in remission, with a mean difference of 14.6 pg/ml (95% CI 5.47, 24.1). When using a cutoff of 2 standard deviations above the healthy donor mean (i.e. 73.3

pg/ml), 27.7 % of MS in relapse samples were above the MOG cutoff. By comparison, when using the cutoff of 2 standard deviations above healthy donor NfL mean (i.e. 9.9 pg/ml), 50% of the MS in relapse samples were above the cutoff. When using either MOG or the NfL cutoff, 56% of MS in relapse samples were above the cutoff.

Correlation between MOG and NfL

The relationship between MOG and NfL levels was assessed for all (cohort 1 and cohort 2) multiple sclerosis samples (Figure 3A). There was a moderate correlation between serum MOG protein and NfL levels (Spearman $r = 0.418$, $p < 0.0001$). MOG to NfL ratio (MOG/NfL) was analyzed for all multiple sclerosis samples as a measure of relative MOG versus NfL levels for a given sample. A frequency histogram was used to visualize the distribution of MOG/NfL ratios among the multiple sclerosis samples with high MOG or NfL levels (i.e. > 2 standard deviations above healthy donor means as shown in quadrants **a**, **b** and **c** of Figure 3A). As shown in Figure 3B, the distribution of MOG/NfL showed slight asymmetry with a modest skew to left representing the relatively few samples that showed high MOG/NfL ratio.

DISCUSSION

In a case-control study, we show that serum MOG protein levels are higher in multiple sclerosis compared to those of healthy donors and primary headache syndromes (non-inflammatory neurological disease controls). ROC curve analysis indicates that serum MOG protein levels provide good discrimination between multiple sclerosis and controls. Blood MOG protein levels were also higher in samples from the cohort of multiple sclerosis patients in clinical relapse compared to those in remission, suggesting that elevated serum MOG levels are associated with disease activity in multiple sclerosis. These results indicate that serum MOG may be a useful biomarker for multiple sclerosis, likely representing the underlying pathology of demyelination. It is plausible that MOG protein is released into the CNS interstitial fluid in the process of inflammatory demyelination, then released into the CSF and eventually into blood circulation. Given our knowledge that humoral autoimmunity specifically directed against native MOG (anti-MOG antibody) is rare in multiple sclerosis (Reindl and Waters 2019), MOG protein is likely to be one of many myelin components released as part of demyelination in multiple sclerosis. Myelin components detected in the CSF such as MBP have been in clinical use and prior research has also examined CSF MOG protein levels as a biomarker of multiple sclerosis (Avsar et al. 2012), but the procedural burden of obtaining CSF limits the utility of CSF biomarkers for routine

monitoring. The results of this study supports the use of serum MOG protein levels as part of a multi-biomarker panel approach to more comprehensively assess MS disease activity. Serum MOG protein levels may complement existing tools such as blood NfL, especially in distinguishing inflammatory demyelination from strictly neurodegenerative disorders or non-inflammatory mimics of MS.

When compared to NfL, MOG protein levels provided incremental additional information in identifying multiple sclerosis in clinical relapse. Whereas 50% of multiple sclerosis in clinical relapse samples were identified by high NfL levels alone, 56% of multiple sclerosis in relapse were identified by the criteria of either high MOG or high NfL levels. These results are in line with that of a recent study that showed that MOG protein was one of a panel of biomarkers associated with disease activity in multiple sclerosis (Chitnis et al. 2024). The concept that NfL alone is inadequate to identify all disease activity in multiple sclerosis is supported by prior research showing that a substantial proportion of those with newly enhancing multiple sclerosis lesions on MRI did not have elevation in blood NfL levels (Fox et al. 2024). Based on the premise that MOG protein and NfL are respectively the byproducts of demyelination and axonal injury, one could ask what MOG and NfL levels tell us about the relative degrees of demyelination and axonal injury resulting from disease activity in multiple sclerosis. We found a moderate correlation between serum MOG and NfL levels, suggesting that demyelination and axonal injury are typically linked by the same underlying pathobiology responsible for disease activity in multiple sclerosis. Of interest to us were the outliers in the MOG versus NfL correlation analysis which showed either high MOG/low NfL or low MOG/high NfL (i.e. quadrants **a** and **c** of Figure 3A). One hypothesis might be that these outliers represent multiple sclerosis endophenotypes defined by those with a predominantly demyelinating (high MOG/low NfL) phenotype versus those with a predominantly neurodegenerative (low MOG/high NfL) phenotype. Alternatively, we think that a more likely explanation is that MOG/NfL ratio reflects lesion evolution in multiple sclerosis where initial demyelination injury sheds MOG protein with subsequent neuroaxonal transection/degeneration releasing NfL. In other words, high MOG/low NfL (Figure 3A quadrant **a**) reflects primary demyelination early in lesion formation, followed by a mixture of demyelination/axonal injury (high MOG/high NfL, Figure 3A quadrant **b**) and progressing to later axonal degeneration (high NfL/low MOG, Figure 3A quadrant **c**) that follows axonal transection. This view is supported by the frequency distribution of MOG/NfL ratio (Figure 3B) which appears to show a single population with a slight skew rather than a bimodal or trimodal distribution. Future prospective studies with serial blood

monitoring over the course of new disease activity in multiple sclerosis are needed to confirm this interpretation.

We found a moderate correlation between paired serum and CSF levels of MOG protein. Other CNS biomarkers studied in multiple sclerosis such as glial acidic fibrillary protein (GFAP) have also shown moderate blood to CSF correlation (Cross et al. 2024). In contrast, NfL levels consistently show strong blood to CSF correlation (Novakova et al. 2017; Kuhle, Barro, Disanto, et al. 2016). The moderate correlation between serum and CSF MOG protein levels suggests that pre-analytical or non-neurological factors may influence blood MOG protein levels. Pre-analytical factors may include the effects of time to processing or freeze-thaw cycles. Non-neurological factors may include kidney function, liver function, other metabolic abnormalities or body mass index (Ramanathan 2024). Another consideration is the possibility of peripheral MOG protein expression. Although MOG protein is primarily expressed in the CNS, low level MOG gene expression in Schwann cells of primates has been reported (Pagany et al. 2003). Further studies are needed to better define pre-analytical, non-neurological factors or extra-CNS sources influencing blood MOG protein levels.

The main limitation of this study is the retrospective case-control design. The archived blood samples were obtained from two biorepositories. Although possible, differences in sample processing are unlikely to explain these results given similar standard operating procedures and given that each cohort was composed of test and internal control subjects. We did not have the appropriate samples to adequately assess the effect of relevant biological variables such as age and sex on blood MOG protein levels. Future prospective studies are needed to further establish MOG protein as a useful biomarker for diagnosis, prognosis, monitoring disease activity and response to therapy in multiple sclerosis.

REFERENCES

Avsar, T., D. Korkmaz, M. Tutuncu, et al. 2012. “Protein Biomarkers for Multiple Sclerosis: Semi-Quantitative Analysis of Cerebrospinal Fluid Candidate Protein Biomarkers in Different Forms of Multiple Sclerosis.” *Multiple Sclerosis* 18 (8): 1081–91. 22252467. https://doi.org/10.1177/1352458511433303.

Brunner, C., H. Lassmann, T. V. Waehneldt, J. M. Matthieu, and C. Linington. 1989. “Differential Ultrastructural Localization of Myelin Basic Protein, Myelin/Oligodendroglial Glycoprotein, and 2’,3’-Cyclic Nucleotide 3’-Phosphodiesterase in the CNS of Adult Rats.” *Journal of Neurochemistry* 52 (1): 296–304. https://doi.org/10.1111/j.1471-4159.1989.tb10930.x.

Chitnis, Tanuja, Ferhan Qureshi, Victor M. Gehman, et al. 2024. “Inflammatory and Neurodegenerative Serum Protein Biomarkers Increase Sensitivity to Detect Clinical and Radiographic Disease Activity in Multiple Sclerosis.” *Nature Communications* 15 (1): 4297. https://doi.org/10.1038/s41467-024-48602-9.

Cross, Anne H., Jeffrey M. Gelfand, Simon Thebault, et al. 2024. “Emerging Cerebrospinal Fluid Biomarkers of Disease Activity and Progression in Multiple Sclerosis.” *JAMA Neurology*, March 11, e240017. https://doi.org/10.1001/jamaneurol.2024.0017.

Fox, Robert J., Bruce A. C. Cree, Jérôme de Sèze, et al. 2024. “Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple Sclerosis.” *Neurology* 102 (9): e209357. https://doi.org/10.1212/WNL.0000000000209357.

Ho, Joses, Tayfun Tumkaya, Sameer Aryal, Hyungwon Choi, and Adam Claridge-Chang. 2019. “Moving beyond P Values: Data Analysis with Estimation Graphics.” *Nature Methods* 16 (7): 565–66. https://doi.org/10.1038/s41592-019-0470-3.

Kuhle, Jens, Christian Barro, Ulf Andreasson, et al. 2016. “Comparison of Three Analytical Platforms for Quantification of the Neurofilament Light Chain in Blood Samples: ELISA, Electrochemiluminescence Immunoassay and Simoa.” *Clinical Chemistry and Laboratory Medicine* 54 (10): 1655–61. https://doi.org/10.1515/cclm-2015-1195.

Kuhle, Jens, Christian Barro, Giulio Disanto, et al. 2016. “Serum Neurofilament Light Chain in Early Relapsing Remitting MS Is Increased and Correlates with CSF Levels and with MRI Measures of Disease Severity.” *Multiple Sclerosis (Houndmills, Basingstoke, England)* 22 (12): 1550–59. https://doi.org/10.1177/1352458515623365.

Novakova, Lenka, Henrik Zetterberg, Peter Sundström, et al. 2017. “Monitoring Disease Activity in Multiple Sclerosis Using Serum Neurofilament Light Protein.” *Neurology* 89 (22): 2230–37. https://doi.org/10.1212/WNL.0000000000004683.

Pagany, Maria, Maja Jagodic, Anna Schubart, et al. 2003. “Myelin Oligodendrocyte Glycoprotein Is Expressed in the Peripheral Nervous System of Rodents and Primates.” *Neuroscience Letters* 350 (3): 165–68. https://doi.org/10.1016/s0304-3940(03)00899-1.

Pribyl, T. M., C. W. Campagnoni, K. Kampf, et al. 1993. “The Human Myelin Basic Protein Gene Is Included within a 179-Kilobase Transcription Unit: Expression in the Immune and Central Nervous Systems.” *Proceedings of the National Academy of Sciences of the United States of America* 90 (22): 10695–99. https://doi.org/10.1073/pnas.90.22.10695.

Ramanathan, Murali. 2024. “Non-Neurological Factors Associated with Serum Neurofilament Levels in the United States Population.” *Annals of Clinical and Translational Neurology* 11 (5): 1347–58. https://doi.org/10.1002/acn3.52054.

Reindl, Markus, and Patrick Waters. 2019. “Myelin Oligodendrocyte Glycoprotein Antibodies in Neurological Disease.” *Nature Reviews. Neurology* 15 (2): 89–102. https://doi.org/10.1038/s41582-018-0112-x.

Thompson, Alan J., Brenda L. Banwell, Frederik Barkhof, et al. 2018. “Diagnosis of Multiple Sclerosis: 2017 Revisions of the McDonald Criteria.” *The Lancet. Neurology* 17 (2): 162–73. https://doi.org/10.1016/S1474-4422(17)30470-2.

Table 1. Demographics of cohort 1 (VCU MS biorepository)

	Multiple sclerosis DMT-naive (N = 28)	**Headache** (N = 25)	p-value
Age, mean (st. dev.)	41.0 (12.2)	38.2 (9.9)	0.39
Sex, female (%)	67	88	0.06
Race (%) white:Black:other	52:41:7	32:68:0	0.11
Acute treatment*	6 (22%)	NA	
On DMT (%)	0	NA	
Serum NfL pg/ml, mean (st. dev.)	18.0 (17.1)	6.2 (3.5)	**0.0003**

*High dose corticosteroids received within 30 days prior to sampling. St. dev., standard deviation. DMT, disease modifying therapy. NA, not applicable. NfL, neurofilament light chain

Table 2. Demographics of cohort 2 (ACP biorepository)

	Multiple sclerosis DMT-naive (N = 33)	**Healthy donor** (N = 36)	p-value
Age, mean (st. dev.)	32.8 (5.7)	30.8 (4.7)	0.09
Sex, female (%)	52	49	0.99
Race (% white)	100	100	0.99
Acute treatment*	9 (27%)	NA	
On DMT (%)	0	NA	
Serum NfL pg/ml, mean (st. dev.)	36.4 (83.2)	6.9 (6.9)	**< 0.0001**

*High dose corticosteroids received within 30 days prior to sampling. St. dev., standard deviation. DMT, disease modifying therapy. NA, not applicable. NfL, neurofilament light chain

Table 3. Demographics of multiple sclerosis in clinical relapse and remission (VCU MS biorepository)

	MS in relapse (N = 36)	**MS in remission** (N = 27)	p-value
Age, mean (st. dev.)	37.9 (9.7)	39.2 (9.2)	0.44
Sex, female (%)	28 (78%)	22 (85%)	0.76
Race (%) white:Black:other	81:19:0	70:30:0	0.38
On DMT (%)	21 (58%)	25 (93%)	**0.0035**
Serum NfL pg/ml, mean (st. dev.)	15.7 (16.2)	7.1 (3.3)	**0.012**

St. dev., standard deviation. DMT, disease modifying therapy. NA, not applicable. NfL, neurofilament light chain



Figure 1. ***Blood MOG protein levels are higher in multiple sclerosis compared to controls.*** A) Cohort 1 (VCU MS biorepository) serum MOG levels for individuals with multiple sclerosis compared to those from individuals with primary headache syndromes. Mean and 95% confidence interval shown as line and error bars. *** $p < 0.001$, Mann-Whitney test. B) Cohort 2 (ACP biorepository) serum MOG levels for multiple sclerosis compared to healthy donors. Mean and 95% confidence interval shown as line and error bars. **** $p < 0.0001$, Mann-Whitney test. C) Receiver operating characteristic (ROC) curve of pooled cohort 1 and cohort 2 MOG data to classify MS versus non-MS controls (healthy donors and primary headache syndromes). D) Correlation between serum and cerebrospinal fluid (CSF) MOG protein levels for cases where paired serum and CSF samples were available (cohort 1). Pearson correlation analysis of log transformed data is shown.



Figure 2. ***Blood MOG protein levels are associated with clinical disease activity in multiple sclerosis***. A) Serum MOG protein levels for individuals with multiple sclerosis in clinical relapse (MS in relapse) compared to those in remission (MS in remission). Mean and 95% confidence interval for serum MOG shown as line and error bars. * $p < 0.05$, Mann-Whitney test.



Figure 3. ***Correlation between MOG and NfL***. A) Serum MOG protein versus serum neurofilament light chain (NfL) levels for subjects with multiple sclerosis (cohort 1 and cohort 2 combined). Dotted lines indicate cutoff values of 2 standard deviations above healthy donor means for MOG (X-axis) and NfL (Y-axis). B) Frequency distribution histogram of MOG/NfL ratio for subjects with multiple sclerosis with high NfL or MOG levels (> 2 standard deviations above the mean).